Prognoses of patients with melanoma who continue/discontinue anti-programmed death-1 therapy after achieving a complete response in a real-world setting: a multicentre retrospective study

Br J Dermatol. 2022 Oct;187(4):594-596. doi: 10.1111/bjd.21276. Epub 2022 Jun 7.
No abstract available

Publication types

  • Letter
  • Multicenter Study

MeSH terms

  • Humans
  • Melanoma* / drug therapy
  • Prognosis
  • Retrospective Studies
  • Syndrome